KEYTRUDA + Chemo Significantly Improved OS vs chemo Alone in With HER2-Neg Gastric or GEJ Adenocarcinoma Patients Regardless of PD-L1 Expression February 22, 2023
FDA grants Fast Track designation for KIN-3248 for the treatment of patients with metastatic cholangiocarcinoma February 22, 2023
US FDA Advisory Committee votes in support of trials designed to evaluate Jemperli as a potential treatment for MMR-D/MSI-high locally advanced rectal cancer February 22, 2023
CARsgen Announces Collaboration Agreement to Evaluate AB011 in Combination with Atezolizumab to Treat Gastric Cancer February 8, 2023
First Patient Dosed in VIRAGE, a Ph 2b Trial of Systemically Administered VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma February 1, 2023
ASCO GI: OS Data for Trifluridine/Tipiracil (LONSURF®) In Combination With Bevacizumab in Patients With Refractory mCRC presented February 1, 2023
Pivotal Data for Futibatinib in Previously Treated Patients With Metastatic Intrahepatic Cholangiocarcinoma published in the NEJM February 1, 2023
ASCO GI: Positive findings in 3L+ metastatic pancreatic cancer patients with doubled OS versus historical OS announced from trial QUILT 88 February 1, 2023
ASCO GI: 84% Overall Survival at 18 Months from Ph 2 Trial Evaluating Zanidatamab in HER2-Expressing Metastatic Gastroesophageal Adenocarcinoma announced February 1, 2023
Pivotal Ph 3 IMbrave050 trial of Tecentriq + Avastin in people with early-stage HCC at high risk of recurrence following surgery met primary endpoint of RFS February 1, 2023
KEYTRUDA® + Chemotherapy Significantly Improved OS Versus Chemotherapy in 1L Biliary Tract Cancer in KEYNOTE-966 Trial February 1, 2023
ASCO GI: Ph 3 NAPOLI 3 trial of Onivyde® regimen demonstrating positive survival results in 1L metastatic pancreatic ductal adenocarcinoma presented February 1, 2023
ASCO GI: Final Results and New Xerna™ TME Panel Biomarker Data from Ph 2 Trial of Bavituximab + Pembrolizumab in 1L HCC Patients announced February 1, 2023
ASCO GI: Ph 2 Data of CTX-009 in Combination with Paclitaxel in Patients with Biliary Tract Cancers (BTC) Presented February 1, 2023
FDA Accelerated Approval of TUKYSA® (tucatinib) + Trastuzumab in Previously Treated RAS WT, HER2-Positive mCRC Patients February 1, 2023
Upcoming 2023 Readouts from Phase 2 and Pivotal Phase 3 Clinical Trials of Trilaciclib announced January 17, 2023
Nouscom and MSD to Evaluate NOUS-209 + KEYTRUDA® in a Ph 2 Randomized Trials in dMMR/MSI-High Metastatic Colorectal Cancer January 11, 2023
Positive Interim Results from Mitazalimab OPTIMIZE-1 Phase 2 Trial in Pancreatic Cancer Exceeding 50% Objective Response Rate Announced January 11, 2023
Results from INTRIGUE Ph 3 Clinical Study Demonstrate Substantial Clinical Benefit of QINLOCK® in 2L GIST Patients with Mutations in KIT Exon 11 and 17/18 Only January 11, 2023
Jazz Pharmaceuticals and Zymeworks Announce Jazz has Confirmed Opt-in and Advances Partnership for Zanidatamab January 4, 2023
